Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyAmyloidosisTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

I have been taking Vyndamax since my diagnosis in June of 2021. I recently asked my cardiologist about adding Amvuttra to my treatment and he said it wasn't for the type of amyloidosis that I have. I know that Vyndamax has been a life saver for me, and other than the worsening of polyneuropathy in my left hand, my condition has improved tremendously since my diagnosis. I'm just curious as to whom Amvuttra is prescribed for, as I thought I'd seen others with the same type amyloidosis that I have… read more

7 days ago
 · 
Reactions
A MyAmyloidosisTeam Member

Have ATTR-CM Have been on both …started on AMVUTTRA one year ago…'I feel that the combination has improved my health. Medicare does approve it .

3 days ago
A MyAmyloidosisTeam Member

Dana , I have so many issues I have to stay clear of Playing Cardiologist I will say that I’m sorry for our condition. & I’ll add you onto my prayer list.

3 days ago
MyAmyloidosisTeam

Great question! It's wonderful to hear that Vyndamax has made such a positive difference for you since your 2021 diagnosis — that's really encouraging.

Amvuttra (vutrisiran) is a gene silencer, meaning it works by reducing how much TTR protein the liver produces. Here's a breakdown of what it's approved for:

- Originally Show Full Answer

Great question! It's wonderful to hear that Vyndamax has made such a positive difference for you since your 2021 diagnosis — that's really encouraging.

Amvuttra (vutrisiran) is a gene silencer, meaning it works by reducing how much TTR protein the liver produces. Here's a breakdown of what it's approved for:

- Originally approved for hereditary ATTR amyloidosis (hATTR) with peripheral neuropathy
- In March 2025, it received additional FDA approval for transthyretin amyloid cardiomyopathy (ATTR-CM) — which does include wild-type ATTR-CM So your cardiologist's answer may have been based on guidance that existed *before* the March 2025 approval. It may be worth revisiting that conversation with your cardiologist now that the approval has expanded to include ATTR-CM.

That said, whether adding Amvuttra makes sense alongside Vyndamax is something only your care team can determine based on your full health picture. It's absolutely worth asking again — especially since you've seen others with wild-type ATTR-CM using it!

7 days ago

Related Questions

View All
A MyAmyloidosisTeam Member asked a question 💭
Richmond BC Canada

A MyAmyloidosisTeam Member asked a question 💭
Barstow, CA